Skip to content

Protein Supplementation for Chronic Stroke Treatment

Incorporating Supplementary Protein Into Rehabilitative Exercise (INSPIRE Trial) for Patients With Chronic Stroke

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03637270
Enrollment
114
Registered
2018-08-17
Start date
2018-12-19
Completion date
2023-04-03
Last updated
2023-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Stroke

Brief summary

Stroke patients usually have difficulties with moving and are venerable to secondary problems such as sarcopenia and strength loss. These problems may accelerate the disability process during aging. It is well known that exercise helps to maintain or promote human fitness. This study is conducted to explore the beneficial effects of exercise and protein supplement on fitness and body composition among patients with chronic stroke.

Detailed description

This is a multicenter randomized control trial. Participants will be recruited from 4 teaching hospitals in Taipei. Participants are randomly assigned to 2 groups: 1. protein supplementation + exercise (PRO group); 2. carbohydrate supplementation + exercise (CHO group); The 1-hour exercise intervention includes aerobic cycling exercise followed by progressive resisted exercise with TheraBand. PRO group receives PS immediately before and after the exercise while the CHO group receive sham product (the same calories with no protein). The Interventions are arranged 3 sessions a week for 10 weeks. The outcome measurements are performed at 0-week, 10-week, and 20-week.

Interventions

DIETARY_SUPPLEMENTDietary supplementation

Before and after each exercise session, the research assistant will give subjects protein supplement or carbohydrate supplement according to the treatment assignment and ask them to drink it down right away.

OTHERExercise training

Including aerobic cycling training and progressive resisted exercise

Sponsors

Taipei Medical University WanFang Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
20 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

1. Chronic stroke\>6months 2. Age : 20-75 y 3. Able to walk independently over 10 mins (with or without orthosis) 4. Able to use stationary bike

Exclusion criteria

1. Physiological condition not stable, cognitive dysfunction, not able to coordinate with examine or treatments. 2. Not able to exercise due to severe cardiopulmonary dysfunction 3. Malnutrition (MNA\<11) 4. Severe obesity (BMI\>35) 5. Renal insufficiency 6. Unable to tolerate our cardiopulmonary exercise test (CPET) (eg, too short stature to fit the machine, leg spasticity is too strong to peddle the cycling, unable to maintain 50 rpm at the beginning of CPET, indications for early termination of CPET based on the American College of Sport Medicine suggestions)

Design outcomes

Primary

MeasureTime frameDescription
Cardiopulmonary capacity10 weeksVO2-peak. Oxygen consumption (VO2- peak) were measured during our cardiopulmonary test (with a ramped stationary biking and a gas analyzer). The workload was increased at a ramp rate of 5-10 W/min. A cadence at 50\ 70 rpm was to be maintained.

Secondary

MeasureTime frameDescription
Timed up and go (TUG)20 weeksmeasures the mixed capacity of balance and walking
Burg Balance Test20 weeksmeasures the balance
CardioPulmonary Exercise Test20 weeksmeasures cardiopulmonary fitness
Total body lean and fat mass20 weeksmeasured by dual energy X-ray absorptiometry
Physical performance (short physical performance battery)20 weeksmeasured by clinical evaluation
Physical performance (modified physical performance test)20 weeksmeasured by clinical evaluation
Maximal isometric voluntary contraction20 weeksmeasured by clinical evaluation
6 minutes walk test20 weeksmeasures the walking endurance

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026